Organigram Global Inc. (NASDAQ: OGI) announced the accelerated integration of Sanity Group GmbH into a unified global operating structure, along with two executive appointments and an amended earnout agreement tied to the original acquisition.

Finn Age Hänsel has been appointed President, Rest of World & Chief Strategy Officer, and Adrian Frenzel has been named Global Chief Operating Officer. Tim Emberg will continue as President, Canada. Hänsel co-founded Sanity in 2018 and previously co-founded Australian online retailer The Iconic. Frenzel previously served as Managing Director and COO of Sanity Group and held roles at McKinsey & Company, Gorillas Technologies and HelloFresh USA.

To enable the integration, Organigram amended the share purchase agreement governing the Sanity acquisition, which had required Sanity to operate on a standalone basis during a 12-month earnout period. The amended agreement fixes the earnout at 85% of the maximum value originally contemplated. Under the revised terms, consideration will consist of €20 million in cash and approximately €76 million payable in Organigram shares, net of pre-acquisition interests and certain deductions. The share price for the equity portion will be based on the 20-day volume-weighted average trading price on the TSX, subject to a floor of C$3.00 and a cap of C$4.00 per share. Payment is due no later than May 1, 2027.

Sanity contributed approximately CAD$40 million to Organigram's consolidated net revenue in the most recent quarter, representing more than 35% of total net revenue, and was accretive to Adjusted EBITDA. Sanity's quarterly revenue rose 34% since December 31, 2025, reaching €25.5 million.

The combined company's supply and commercial network will span Canada, Germany, Switzerland, Poland, Czechia, the United Kingdom and Australia. Organigram currently supplies bulk cannabis to Germany, Australia and the U.K. and recently launched 10 product SKUs in the Australian medical cannabis market.

The amended earnout agreement constitutes a related party transaction under Multilateral Instrument 61-101 but is exempt from formal valuation and minority shareholder approval requirements.